Artal Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Artal Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-500,000	Closed	-$7.02M	–	137
2017 Q3	$6.34M	Sell	500,000 -260,000	-34%	-$3.31M	0.11%	57
2017 Q2	$9.02M	Sell	760,000 -40,000	-5%	-$498K	0.16%	39
2017 Q1	$11.8M	Buy	800,000 +300,000	+60%	+$4.86M	0.26%	35
2016 Q4	$8.09M	Buy	500,000 +150,000	+43%	+$2.72M	0.18%	41
2016 Q3	$6.35M	Hold	350,000	–	–	0.13%	47
2016 Q2	$5.76M	Buy	+350,000	New	+$5.66M	0.12%	39

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Artal Group's HZNP Position: Q4 2017 in Review

Artal Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 500,000 shares — an estimated $7.02M sold.

Artal Group first reported a position in HZNP in Q2 2016 and held it in 6 quarters. The position peaked at $11.8M in Q1 2017. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

Artal Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Artal Group sold 500,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $7.02M.
Artal Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 6 quarters.
Artal Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11.8M in Q1 2017.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.